Scinai Immunotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1.31	0.66	-	-	-
Revenue Growth (YoY)	99.24%	-	-	-	-
Cost of Revenue	-3.96	-1.24	-	-	-
Gross Profit	-2.65	-0.58	-	-	-
Selling, General & Admin	-2.52	-2.53	-4.51	5.3	7.63
Research & Development	-2.37	-5.53	-5.21	5.77	3.25
Other Operating Expenses	-	-	0.01	-	-0.01
Total Operating Expenses	-4.89	-8.06	-9.71	11.06	10.86
Operating Income	2.24	7.48	9.71	-11.06	-10.86
Total Non-Operating Income (Expense)	-	14.76	-	-5.27	-2.66
Pretax Income	2.24	22.24	9.71	-16.33	-13.52
Net Income	2.24	22.24	9.71	-16.33	8.21
Net Income to Common	2.24	22.24	9.71	-16.33	8.21
Net Income Growth	-89.94%	129.11%	-	-	-
Shares Outstanding (Basic)	2	1	0	0	0
Shares Outstanding (Diluted)	2	1	0	0	0
Shares Change (YoY)	189.55%	106.41%	107.22%	33.56%	27.37%
EPS (Basic)	3.60	-	16.00	40.00	-80.00
EPS (Diluted)	3.60	-	16.00	40.00	-80.00
EPS Growth	-	-	-60.00%	-	-
Shares Outstanding	3.47	0.85	0.46	0.25	0.18
Free Cash Flow	-6.06	-6.35	-10.02	-8.1	-7.57
Free Cash Flow Per Share	-2.59	-7.87	-25.65	-42.97	-53.60
Gross Margin	-202.29%	-88.15%	-	-	-
Operating Margin	170.71%	1136.47%	-	-	-
Profit Margin	170.71%	3379.48%	-	-	-
FCF Margin	-461.86%	-964.59%	-	-	-
EBITDA	3.66	9.13	10.22	-10.5	-10.39
EBITDA Margin	279.10%	1387.08%	-	-	-
EBIT	2.24	7.48	9.71	-11.06	-10.86
EBIT Margin	170.71%	1136.47%	-	-	-

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q